TY - JOUR
T1 - Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis
AU - Radue, Ernst Wilhelm
AU - O'Connor, Paul
AU - Polman, Chris H.
AU - Hohlfeld, Reinhard
AU - Calabresi, Peter
AU - Selmaj, Krystof
AU - Mueller-Lenke, Nicole
AU - Agoropoulou, Catherine
AU - Holdbrook, Frederick
AU - De Vera, Ana
AU - Zhang-Auberson, Lixin
AU - Francis, Gordon
AU - Burtin, Pascale
AU - Kappos, Ludwig
PY - 2012/10
Y1 - 2012/10
N2 - Objective: To assess the impact of fingolimod (FTY720) therapy on magnetic resonance imaging measures of inflammatory activity and tissue damage in patients participating in a 2-year, placebo-controlled, phase 3 study. Design: Patients with active relapsing-remitting multiple sclerosis were randomized to receive fingolimod, 0.5 mg; fingolimod, 1.25 mg; or placebo for 2 years. Standardized magnetic resonance imaging scans were obtained at months 0, 6, 12, and 24 and centrally evaluated for number and volume of T1 gadolinium-enhancing, T2 hyperintense, and T1 hypointense lesions and for percentage of brain volume change. Findings were compared across subgroups by treatment and baseline characteristics. Setting: Worldwide, multicenter clinical trial. Patients: Patients were part of the fingolimod FTY720 Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) clinical trial for relapsing-remitting multiple sclerosis (N=1272). Main Outcome Measures: We measured the effect of therapy on acute inflammatory activity, burden of disease, and irreversible loss of brain volume. Results: Fingolimod therapy resulted in rapid and sustained reductions in inflammatory lesion activity as assessed by gadolinium-enhancing and new/newly enlarged T2 lesions after 6, 12, and 24 months of therapy (P < .001, all comparisons vs placebo). Changes in T2 hyperintense and T1 hypointense lesion volume also significantly favored fingolimod (P < .05, all comparisons). Fingolimod, 0.5 mg (licensed dose), significantly reduced brain volume loss during months 0 to 6, 0 to 12, 12 to 24, and 0 to 24 (P < .05, all comparisons) vs placebo, and subgroup analyses confirmed these effects over 2 years irrespective of the presence/absence of gadolinium-enhancing lesions, T2 lesion load, previous treatment status, or level of disability. Conclusion: These results, coupled with the significant reductions in relapse rates and disability progression reported previously, support the positive impact on long-term disease evolution. Trial Registration: clinicaltrials.gov Identifier: NCT00289978.
AB - Objective: To assess the impact of fingolimod (FTY720) therapy on magnetic resonance imaging measures of inflammatory activity and tissue damage in patients participating in a 2-year, placebo-controlled, phase 3 study. Design: Patients with active relapsing-remitting multiple sclerosis were randomized to receive fingolimod, 0.5 mg; fingolimod, 1.25 mg; or placebo for 2 years. Standardized magnetic resonance imaging scans were obtained at months 0, 6, 12, and 24 and centrally evaluated for number and volume of T1 gadolinium-enhancing, T2 hyperintense, and T1 hypointense lesions and for percentage of brain volume change. Findings were compared across subgroups by treatment and baseline characteristics. Setting: Worldwide, multicenter clinical trial. Patients: Patients were part of the fingolimod FTY720 Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) clinical trial for relapsing-remitting multiple sclerosis (N=1272). Main Outcome Measures: We measured the effect of therapy on acute inflammatory activity, burden of disease, and irreversible loss of brain volume. Results: Fingolimod therapy resulted in rapid and sustained reductions in inflammatory lesion activity as assessed by gadolinium-enhancing and new/newly enlarged T2 lesions after 6, 12, and 24 months of therapy (P < .001, all comparisons vs placebo). Changes in T2 hyperintense and T1 hypointense lesion volume also significantly favored fingolimod (P < .05, all comparisons). Fingolimod, 0.5 mg (licensed dose), significantly reduced brain volume loss during months 0 to 6, 0 to 12, 12 to 24, and 0 to 24 (P < .05, all comparisons) vs placebo, and subgroup analyses confirmed these effects over 2 years irrespective of the presence/absence of gadolinium-enhancing lesions, T2 lesion load, previous treatment status, or level of disability. Conclusion: These results, coupled with the significant reductions in relapse rates and disability progression reported previously, support the positive impact on long-term disease evolution. Trial Registration: clinicaltrials.gov Identifier: NCT00289978.
UR - http://www.scopus.com/inward/record.url?scp=84867362418&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84867362418&partnerID=8YFLogxK
U2 - 10.1001/archneurol.2012.1051
DO - 10.1001/archneurol.2012.1051
M3 - Article
C2 - 22751847
AN - SCOPUS:84867362418
SN - 0003-9942
VL - 69
SP - 1259
EP - 1269
JO - Archives of neurology
JF - Archives of neurology
IS - 10
ER -